

Correction to: “Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee”

In the above-named article Carmina E, Dreno B, Lucky WA, Agak WG, Dokras A, Kim JJ, Lobo RA, Tehrani FR, and Dumesic D (*J Endo Society*. 2022; 6(3); doi: [10.1210/jendso/bvac003](https://doi.org/10.1210/jendso/bvac003)), the article contained a recommendation that the authors wish to correct following reconsideration:

In the section Treatment of Female Adult Acne, the statement “Now no products containing cyproterone acetate should be used in acne or in other hyperandrogenic

conditions” is deleted and replaced by “While this association has been proved only in patients using daily doses of cyproterone acetate of 10 mg or more, it is the opinion of the Committee that prolonged use of estroprogestins containing low doses of cyproterone should be avoided in patients with acne.”

The article has been corrected online.

doi: [10.1210/jendso/bvac003](https://doi.org/10.1210/jendso/bvac003)